Major cannabis companies experienced their most impressive weekly performance of the year following an FDA announcement regarding CBD product enforcement. The regulatory shift propelled leading cannabis stocks significantly higher and positioned the sector for its strongest weekly showing in months.
In a Wednesday correspondence, FDA Commissioner Marty Makary indicated the agency would refrain from enforcing specific sections of the Federal Food, Drug, and Cosmetic Act against hemp-sourced oral products solely due to CBD content. This enforcement discretion extends to items marketed as dietary supplements and products administered under physician supervision.
Cannabidiol, or CBD, represents a non-intoxicating component of cannabis plants. Consumers utilize it for various wellness applications, and it appears in numerous health and lifestyle products.
The cannabis sector’s upward momentum started Tuesday, preceding the White House and FDA’s launch of a four-part meeting series with industry representatives to address CBD compliance and enforcement strategies.
This FDA policy shift complements President Trump’s December executive action, which rescheduled marijuana from Schedule I to Schedule III classification under federal drug regulations. That directive also tasked the FDA, National Institutes of Health, and Centers for Medicare and Medicaid Services with developing pathways to broaden CBD access for therapeutic applications.
Cannabis equities experienced a temporary boost following December’s executive order before retracing gains. The industry continues to grapple with challenges including limited banking services, stock exchange listing restrictions, and interstate trade barriers stemming from federal regulations.
Tilray emerged as a standout performer during this week’s rally. Shares climbed 6.7% in Thursday’s session alone, positioning it among the sector’s highest by dollar volume. The enterprise conducts research, cultivation, processing, and distribution of medical cannabis throughout numerous nations including Canada, Germany, Australia, and Argentina.
Tilray Brands, Inc., TLRY
Canopy Growth advanced 2.6% during Thursday trading. The organization markets cannabis and hemp-based products for recreational and therapeutic purposes across the US, Canada, Germany, and additional global markets. Its operations include the Storz and Bickel division, which manufactures cannabis vaporization devices. Canopy joined Tilray as one of the week’s most actively traded cannabis equities.
Canopy Growth Corporation, CGC
Curaleaf delivered the most impressive gains among major cannabis companies Thursday, surging 8.4%. This domestically-focused cannabis enterprise has captured significant investor attention as market participants monitor potential federal policy changes that could enable cross-state commerce for cannabis operations.
The AdvisorShares Pure US Cannabis exchange-traded fund climbed 4.6% Thursday and advanced 16% across the week, tracking toward its strongest weekly gain since December.
An industry expert observed the policy represents a “narrowly scoped” approach that falls short of establishing a comprehensive framework for the wider cannabis marketplace, urging Congressional legislative action.
The FDA conducted its initial stakeholder discussion on CBD policy Wednesday, with three additional sessions planned in the continuing series.
The post FDA CBD Policy Shift Triggers Massive Rally in Cannabis Stocks appeared first on Blockonomi.


